A new nanospray drying method for the preparation of nicergoline pure nanoparticles
Source abstract
Abstract
Three different batches of pure nanoparticles (NPs) of nicergoline (NIC) were prepared by spray drying a water:ethanol solution by a new Nano Spray Dryer Buchi B-90. Spherical pure NPs were obtained, and several analytical techniques such as differential scanning calorimetry and X-ray powder diffractometry permitted to assess their amorphous character. A comparison of the solubility, intrinsic dissolution, and drug release of original particles and pure amorphous NPs were determined, revealing an interesting improvement of biopharmaceutical properties of amorphous NPs, due to both amorphous properties and nanosize dimensions. Since in a previous work, the high-thermodynamic stability of amorphous NIC was demonstrated, this study is addressed toward the formulation of NIC as pure amorphous NPs.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems · Analytical Chemistry and Chromatography
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Ahlneck C, Zografi G (1990) The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int J Pharm 62:87–9510.1016/0378-5173(90)90221-O ↗
2. Andronis V, Yoshioka M, Zografi G (1997) Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J Pharm Sci 86:346–35110.1021/js9602711 ↗
3. Banakar UV (1992) In: Swarbrick J (ed) Pharmaceutical dissolution testing. Marcel Dekker, New York, pp 55–105
4. Brossi A (1990) The alkaloids. Chemistry and pharmacology, 38. Academic Press Inc, San Diego, p 142
5. Crowley KJ, Zografi G (2002) Water vapour absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions. J Pharm Sci 90:2150–216510.1002/jps.10205 ↗
6. Elversson J, Millqvist-Fureby A, Alderborn G, Eloffson U (2003) Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying. J Pharm Sci 92:900–91010.1002/jps.10352 ↗
7. Gao L, Zhang D, Chen M (2008) Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res 10:845–86210.1007/s11051-008-9357-4 ↗
8. Goo D, Palosi E, Szporny L (1988) Comparison of the effects of vinpocetine, vincamine, and nicergoline on the normal and hypoxia-damaged learning process in spontaneously hypertensive rats. Drug Dev Res 15:75–8510.1002/ddr.430150108 ↗
9. Hamaura T, Newton JM (1999) Interaction between water and poly(vinylpyrrolidone) containing polyethylene glycol. J Pharm Sci 88:1228–123210.1021/js980354c ↗
10. Hancock BC, Parks M (2000) What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397–40310.1023/A:1007516718048 ↗
11. Heitz C, Descombes JJ, Miller RC, Stoclet JC (1986) α-Adrenoceptor antagonistic and calcium antagonistic effects of nicergoline in the rat isolated aorta. Eur J Pharmacol 123:279–28510.1016/0014-2999(86)90669-2 ↗
12. ICH Topic Q 1 A (R2) (2003) Stability testing of new drug substances and products. Note for guidance on stability testing: stability testing of new drug substances and products. (CPMP/ICH/2736/99). EMEA, London, pp 1–20
13. Junghanns JAH, Müller RH (2008) Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 3:295–309
14. Kontny MJ, Zografi G (1995) Sorption of water by solids. In: Brittain HG (ed) Physical characterization of pharmaceutical solids. Marcel Dekker, New York, pp 387–41810.1201/b14204-13 ↗
15. Maa YF, Nguyen PA, Sweeney T, Shire SJ, Hsu CC (1999) Protein inhalation powders: spray drying vs spray freeze drying. Pharm Res 16:249–25410.1023/A:1018828425184 ↗
16. Malaj L, Censi R, Capsoni D, Pellegrino L, Bini M, Ferrari S, Gobetto R, Massarotti V, Di Martino P (2011) Characterization of nicergoline polymorphs crystallized in several organic solvents. J Pharm Sci 100:2610–262210.1002/jps.22477 ↗
17. Martena V, Censi R, Hoti E, Malaj L, Di Martino P (2011) Physicochemical characterization of nicergoline and cabergoline in its amorphous state. J Therm Anal Calorim doi: 10.1007/s10973-011-1954-210.1007/s10973-011-1954-2 ↗
18. Mauludin R, Müller RH, Keck CM (2009) Development of an oral rutin nanocrystal formulation. Int J Pharm 370:202–20910.1016/j.ijpharm.2008.11.029 ↗
19. Merisko-Liversidge E (2002) Nanocrystals: resolving pharmaceutical formulation issues associated with poorly water-soluble compounds. In: Marty JJ (Ed) Particles. Marcel Dekker, Orlando
20. Noyes A, Whitney WR (1897) The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930–93410.1021/ja02086a003 ↗
21. Pastoris O, Vercesi L, Allorio F, Dossena M (1988) Effect of hypoxia, aging and pharmacological treatment on muscular metabolites and enzyme activities. Il Farmaco Ed Sci 43:627–642
22. Schmitt E, Davis CW, Long ST (1996) Moisture-dependent crystallization of amorphous lamotrigine mesylate. J Pharm Sci 85:1215–121910.1021/js9600484 ↗
23. Shamblin SL, Zografi G (1999) The effects of absorbed water on the properties of amorphous mixtures containing sucrose. Pharm Res 16:1119–112410.1023/A:1018960405504 ↗
24. Shegokar R, Müller RH (2010) Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 399:129–13910.1016/j.ijpharm.2010.07.044 ↗
25. Speiser PP (1998) Poorly soluble drugs: a challenge in drug delivery. In: Benita S, Böhm B, Müller RH (eds) Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Medpharm Scientific Publishers, Stuttgart, pp 15–28
26. Taylor LS, Shamblin SL (2009) Amorphous solids. In: Brittain HG (ed) Polymorphism. Informa Healthcare, New York, pp 594–596
27. Triulzi E, Devizzi S, Margonato A (1981) Use of nicergoline in acute myocardial infarction with diastolic hypertension. Il Farmaco (ed Prat) 36:449–455
28. Venn RD (1980) Review of clinical studies with ergots in gerontology. In: Goldstein M, Liberman A, Calne DB, Thorner MO (eds) Ergot compounds and brain function. Raven Press, New York, pp 363–377
29. Zografi G (1988) States of water associated with solids. Drug Dev Ind Pharm 14:1905–192610.3109/03639048809151997 ↗